Estimation of the comparative therapeutic superiority of QD and BID dosing regimens, based on integrated analysis of dosing history data and pharmacokinetics
- 12 May 2007
- journal article
- research article
- Published by Springer Nature in Journal of Pharmacokinetics and Pharmacodynamics
- Vol. 34 (4) , 549-558
Abstract
Once-daily dosing almost invariably shows a slightly higher percentage of prescribed doses taken than does twice-daily dosing. Many pharmaceutical scientists, regulators, and prescribers have considered this finding to signify the therapeutic superiority of once-daily dosing. The therapeutically more relevant question, however, is not the percentage of prescribed doses taken but the comparative impact of missed doses on the pharmacologic effects of a drug under the two dosing regimens. A key point in this regard is that the pharmacokinetic equivalent of a single missed once-daily dose is 2–3 sequentially omitted twice-daily doses. Thus, an important parameter in comparing the two regimens is the probability of two or three twice-daily doses being sequentially omitted, versus the probability of missing a single once-daily dose. Our data indicate that the probability of sequential omission of 2–3 twice daily doses is half the probability of omission of a single once-daily dose. For that reason, a twice-daily regimen could prove to be superior to a once-daily regimen in maintaining drug concentrations within a therapeutically desirable range. A more important consideration, however, is to maintain not just the concentration of drug in plasma, but the drug’s therapeutic action. The duration of therapeutic drug action following a last-taken dose is not only drug-specific, but also, for some drug, dependent on the pharmacodynamic properties. Judging the comparative superiority of one dosing regimen over another requires knowledge of the drug’s duration action after a last-taken dose, plus knowledge of the comparative probabilities of the various patterns of dose omission. When applied to HIV protease inhibitors, a twice-daily regimen appears to be better than an once-daily regimen in maintaining therapeutically effective drug actions.Keywords
This publication has 8 references indexed in Scilit:
- Less is More: Medicines that Require Less Frequent Administration Improve Adherence, but Are They Better?PharmacoEconomics, 2006
- Patient adherence to prescribed antimicrobial drug dosing regimensJournal of Antimicrobial Chemotherapy, 2005
- Successful Projection of the Time Course of Drug Concentration in Plasma During a 1‐Year Period From Electronically Compiled Dosing‐Time Data Used as Input to Individually Parameterized Pharmacokinetic ModelsThe Journal of Clinical Pharmacology, 2005
- Major features of dose omissions in 87 ambulatory drug trialsClinical Pharmacology & Therapeutics, 2005
- Measurement of Adherence to Antiretroviral MedicationsJAIDS Journal of Acquired Immune Deficiency Syndromes, 2002
- A systematic review of the associations between dose regimens and medication complianceClinical Therapeutics, 2001
- Adherence to Protease Inhibitor Therapy and Outcomes in Patients with HIV InfectionAnnals of Internal Medicine, 2000
- Comparing compliance patterns between randomized treatmentsControlled Clinical Trials, 1997